BioClinica Reports Flat Earnings, Adjusts 2010 EPS Guidance

Wednesday, May 5, 2010 01:07 PM

BioClinica’s first quarter 2010 earnings were flat compared with the same period 2009, with service revenues of $14.7 million. First quarter revenues last year were $14.5 million. Net income was $711,000, or $0.05 per diluted share, compared with $786,000, or $0.05 per diluted share for Q1 2009.

The company, which acquired clinical trial management software company TranSenda a month ago, reiterated its full-year 2010 service revenue forecast of $61 million to $65 million, but revised its earnings per share estimate to be in the range $0.23 to $0.27 per share (down from $0.25 to $0.29) to account for the financial impact of the TranSenda transaction.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs